The Lymphatic Malformation Institute is accepting Letters of Intent for its Pilot Award 2024. This prestigious award, capped at $75,000, supports a one-year exploratory research period, to develop and test exciting new hypotheses or research approaches that have the potential to significantly advance our understanding and/or treatment of Complex Lymphatic Anomalies which include Central Conducting Lymphatic Anomaly (CCLA), Generalized Lymphatic Anomaly (GLA), Gorham Stout Disease (GSD), or Kaposiform Lymphangiomatosis (KLA). Areas of interest include, but are not limited to, genetic analysis, biomarker identification, preclinical model development and characterization, imaging, and single-cell RNA sequencing of animal or patient samples.
March 8th, 2024 - Submission deadline for the Letter of Intent. Please ensure your LOI is sent to email@example.com by 11:59 PM CST.
May 24th, 2024 - Final deadline for invited investigators to submit their full grant proposals. Submissions should reach the same email by 11:59 PM CST.
Learn More >
The application, instructions, and required documents can be found on here. For any queries or further assistance, feel free to contact Michael Dellinger, PhD, Associate Professor, UT Southwestern Medical Center, at firstname.lastname@example.org.
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit research organization that seeks to empower patients and others with actionable information about their health and healthcare choices. We fund comparative clinical effectiveness research (CER), which compares two or more medical treatments, services, or health practices to help patients and other stakeholders make better informed decisions.
On Jan. 9, 2024, PCORI will begin accepting Letters of Intent for PCORI Funding Announcements (PFAs). Register for an Applicant Town Hall today to learn more about upcoming PFAs.
PCORnet® is intended to improve the nation’s capacity to efficiently conduct patient-centered health research, particularly CER, by providing a large, highly representative network of health data, research expertise and patient insights. Read the latest post to learn more about the advantages of using PCORnet for your research, including four new tools aimed at enabling you to maximize every aspect of your research.Learn More >
This notice (#NOT-HL-23-099) was issued by National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), and National Center for Complementary and Integrative Health (NCCIH).
This NOSI aims to promote research on the normal biology of the lymphatic system (LS) and ascertain factors that account for individual differences in the LS impacting resilience. Also of interest is research to identify factors that account for individual differences in pathobiology and response to treatments, and understand the mechanisms and potential novel therapeutics for lymphatic diseases (LDs) and secondary heart, lung, blood, and sleep (HLBS) disorders related to lymphatic dysfunction. Further, this notice intends to stimulate lymphatic research at molecular, cellular, tissue, organ, and whole-body levels, and aims to facilitate research on innovations for identifying and intervening in LDs across the lifespan and disease states. The NOSI may also reach a broader community and facilitate multidisciplinary research needed to determine the function and role LS in health, disease prevention, and to identify biomarkers and test prevention and treatment strategies with specific attention to social determinants of health, and both treatment and health inequities.
This notice applies to due dates on or after October 5, 2023, and subsequent receipt dates through September 7, 2026. This NOSI expires on September 8, 2026; thus no applications will be accepted on or after September 8, 2026.
For more information, click here.Learn More >
The CDMRP originated in 1992 via a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders-the American public, the military, and Congress.
Hallmarks of the CDMRP include:
- investing in groundbreaking research
- targeting critical gaps
- reviewing application using a two-tier formal review with no standing peer review panels and no “pay line”
- involving consumer advocates throughout the program cycle
- supporting both the next generation of researchers and established scientists.
- funding the full pipeline of research development, including basic, translational, and clinical research.
- fostering (or employing) collaboration and synergy
The CDMRP fills research gaps by funding high impact, high risk and high gain projects that other agencies may not venture to fund. While individual programs are unique in their focus, all of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. The CDMRP strives to transform health care for Service Members and the American public through innovative and impactful research.
The 2024 AVF-JOBST Clinical Research Grant will provide a $85,000 grant over two years for original, clinical research in venous diseases, lymphatic diseases, or lipedema with an emphasis on:
- Prevention of disease and its progression
- Diagnosis of disease
- The science of management of the above conditions, especially with compression therapy
This opportunity is open to:
- Residents and fellows in a training program located in the United States
- Physicians who have completed their training within the past ten (10) years and are currently based in the United States
- Applicants who have not previously received this award
Either the applicant or their mentor must be an AVF Member at the time of submission. The awardee is expected to join the AVF and maintain their membership for the duration of the grant period.
Submission deadline: Friday, September 1, 2023
For more information regarding eligibility and the application process or to submit an application, click here.Learn More >
NIH has requested that LE&RN assemble and deliver to NIH a list of lymphatic researchers who are willing to serve on NIH Study Sections. They have identified the following three Study Sections that review lymphatic grant proposals:
* Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.
* Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.
* Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.
If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:
* Study Section(s) on which you are willing to serve
* In 50 words or less, your qualifications for each Study Section selected
* Include CV
Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.